Pulmonary arterial hypertension targeted for new treatment by 9 1Ãâ·Ñ°æÏ of Sheffield scientists
Scientists at the 9 1Ãâ·Ñ°æÏ of Sheffield, working in collaboration with drug and vaccine developer Kymab Ltd, Cambridge, have identified a novel antibody that has the potential to become a new treatment for pulmonary arterial hypertension (PAH).